Stem Cell Research and Regenerative Medicine

Extended Abstract Open Access

Thrombotic and bleeding risks: how best to balance in real world

Syed Raza

Awali Hospital, Bahrain

Keywords: Thrombotic, Cardiac diseases, Atrial fibrillation and Coronary artery disease

ABSTRACT:

Antithrombotic treatment has revolutionized the medical management of cardiac patients. Over the past 20 years, the improvement of recent anti-thrombotic medications and schemes has decreased ischemic events very significantly. With every approach to decrease thrombosis, however, there is an accompanying risk of improving bleeding complications. Conversely, decreasing bleeding complications may increase thrombotic (ischemic) events. Due to increasing number of elderly populations, prevalence of thrombosis related complications and bleeding combined with anti-thrombotic therapy is constantly increasing. There are various tools to evaluate thrombotic risk but evaluation of bleeding risk is often neglected. Thrombosis and bleeding both increase impairment and death or mortality. Balancing both ends of the spectrum is important and a single approach to therapy is advocated. The author will show various strategies to stable the thrombotic and bleeding risk assessment. This demonstration will be of interest to physicians, cardiologists, haematologists, surgeons, anaesthetists and nurses.

Cardiac diseases such as atrial fibrillation (AF) with chance of systemic embolism and death. It presents rheumatic etiology in up to 32% of improving countries, whose anticoagulation and evaluated data are scarce. There was no combination between cardiac death and heart valvular diseases. Independent predictors of cardiac death were reduced measures of hypertension, increase results cardiovascular diseases classification and the existence of systolic ventricular dysfunction. high generality of rheumatic valve disease, there was an under application of oral anticoagulant, in spite of lower bleeding scores and thromboembolism in relation to those reported in the literature.

Significant thrombocytopenia is general in cardiac patients with hematologic malignancies and solid tumors. Many agents that cause thrombocytopenia, such as platinum-based chemotherapy and gemcitabine, are also combined with increased thrombotic risk. Anticoagulant medications are generally used for the control and treatment of thrombo embolism. Although highly productive, they are also combined with significant bleeding risks. Numerous individual clinical factors have been linked to an improved risk of haemorrhage which including older age, anemia, and renal disease. To help quantify of hemorrhage risk for individual cardiac patients, a number of clinical risk examination tools have been developed. These risk evaluation tools changes in how they were derived and how they identify and individual risk factors. At present, their capacity to effectively evaluate anticoagulant-associated hemorrhage remains adequate. Usage of risk forecasting tools to evaluate bleeding in clinical practice is most powerful when applied to patients at the under spectrum of thromboembolic risk, when the chance of hemorrhage will more strongly impact clinical decisions about anti coagulation. Using risk tools may also assist counsel and notify patients about their potential chance for hemorrhage while on anticoagulants, and can recognize patients who might get gained from more careful management of anti-coagulation. Most of the hemorrhage risk strategy were expanded from cohorts of patients newly prescribed or already taking anticoagulants, and as such reflect patients who were considered acceptable for anti-coagulation treatment. Patients with exceptionally high bleeding risk may therefore not be well-represented by these risk tools, as they are smaller likely to be deemed fit for anti-coagulation. Several risk strategies were particularly improved for patients with atrial fibrillation and others in cohorts of venous thrombo embolism and so some risk results which contain disease-particular risk factors. The Outpatient Bleeding Risk Index (OBRI) was the only one that had a associated class of indications for anti coagulation and was importantly developed in a group of patients newly starting warfarin for cardiac surgery or prosthetic heart valves. Other risk plans were developed in subgroup of clinical trial participants community-based outpatients or newly hospitalized patients. Differences in the deriving populations provided to higher and lower observed bleeding rates. In addition to the risk results had differentiation in how they identified or defined bleeding events, as well as what clinical risk factors were obtainable to be tested.

Main thrombotic and bleeding risks were a association of myocardial infarction, definite or probable stent thrombosis or ischemic stroke, and GUSTO (Global Utilization of Streptokinase and tissue Plasminogen Activator for Occluded Coronary Arteries) average or severe bleeding. Thrombotic and bleeding risk gives demonstrated modest accuracy in stratifying thrombotic and bleeding risks; however, a large proportion of cardiac patients at higher thrombotic risk also had increased bleeding risk. Our scores would give clinicians determining therapy strategies for anti-thrombotic therapy with individual risks of thrombotic and bleeding risk events after percutaneous coronary intervention. Further studies are wanted to look over for optimal antithrombotic therapy in the population at increase thrombotic risk for which bleeding risk is also considerable.

Prolonged period of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) was shown to remarkably decrease the chance of myocardial infarction (MI) and stent thrombosis (ST) related with aspirin monotherapy in the DAPT (Dual Antiplatelet Therapy) trial. These results propose that predicting the risk of thrombotic and bleeding events is major for determining the strength of antithrombotic therapy, including the period of DAPT after PCI in individual patients. The DAPT score was improved to differentiate between ischemic high-risk patients and bleeding high-risk patients by using a single scoring system within the DAPT study, it successfully recognised those patients who could gained from prolonged DAPT without excessive bleeding risk. An incremental improvement in the incidence of primary thrombotic and bleeding events were noticed with increased bleeding risk results in patients with high thrombotic risk scores. The aim of anticoagulation is to treat the current Venous thrombo embolism and to control recurrent thrombo embolism. However, anticoagulation also imposes a high risk for bleeding events and this chance must be

Stem Cell Research and Regenerative Medicine

Extended Abstract Open Access

assessed to decide appropriateness of a given therapy plan for each cardiac patient.

Some cardiac patients with coronary artery disease (CAD) have signal for two antiplatelet agents and anticoagulant therapy. CAD patients with atrial fibrillation (AF) who have newly undertaken coronary artery stenting or who have had an acute coronary syndrome (ACS) but were give treatment medically are examples. These individuals are a clinical confront with regard to the need to balance the advantage and chance from this intensive antithrombotic treatment.

The usage of two antiplatelet medium is considered as dual antiplatelet therapy (DAPT); DAPT plus anticoagulant has been known as "triple oral antithrombotic therapy" or "triple therapy". The term "combined antithrombotic therapy" can be used. While the usage of three antithrombotic agents may decrease the rate of cardiac ischemic events, the risk of bleeding is significantly improved related with one or two antithrombotic agents. The evidence is increasing that two antithrombotic agents such as an oral anticoagulant and a P2Y12 inhibitor) is a better option than three for some patients given the increase bleeding risk combined with the usage of triple therapy.

This topic will give the clinician with a guide for selecting the antithrombotic regimen for cardiac patients with an indication for associated antithrombotic therapy after coronary artery stenting. Cardiac patients with an ACS handled medically (no stenting) who need oral anticoagulation are considered individually.